GenEng News  12 hrs ago  Comment 
Cortendo said today it will expand its rare-disease pipeline by acquiring one drug candidate and licensing another, in deals totaling up-to-$140 million-plus—as well as fund future development of the compounds by raising about $33.2 million...
newratings.com  May 15  Comment 
BASEL (dpa-AFX) - Microbix Biosystems Inc. (MBX.TO) announced the District Court in Texas has ruled in favour of Novartis, the defendant, in an infringement suit related to the 18 patent claims asserted by Microbix on its patent 7,270,990 in the...
FierceBiotech  May 14  Comment 
Biotech investor MPM Capital has put together a $400 million new fund with help from Big Pharma, scouting for innovative startups with an eye on build-to-buy deals.
FiercePharma  May 14  Comment 
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.
Market Intelligence Center  May 14  Comment 
After closing Wednesday at $102.67, Novartis AG (NVS) presents an attractive opportunity to get a 3.34% return in just 155 days, which is an annualized return of 7.86% (for comparison purposes only). To enter this trade, sell one Oct. '15 $100.00...
FiercePharma  May 8  Comment 
Amgen is none too eager for Novartis to roll out its newly FDA-approved biosimilar version of its blockbuster Neupogen, and for now, it's getting its way: A U.S. appeals court has blocked sales of the copycat while the companies resolve a patent...
newratings.com  May 8  Comment 
Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC Novartis International AG / Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with...
FierceBiotech  May 6  Comment 
Oxford BioMedica has secured a $50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. The first tranche of money will help OXB service its CAR-T alliance with Novartis.
Wall Street Journal  May 6  Comment 
GlaxoSmithKline cut the amount of money it plans to return to shareholders under an asset swap with Switzerland’s Novartis in a move to shield investors from a dividend cut.
FiercePharma  May 1  Comment 
An Express Scripts unit agreed to settle claims with the U.S. Department of Justice that it participated in a scheme with Novartis that ended in improper government reimbursements. And if the DOJ has its way, the settlement could lead to more...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki